(Originally published on 9/10/2021; last updated on 12/7/2021)
IPOs occur when private companies go public (offer shares to the public for the 1st time)
The last several years have seen a hot biotech IPO market
BPIQ.com continuously adds newly IPOd companies and their clinical assets to our database
Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter
Initial public offerings (IPOs) occur when private companies "go public", which means they offer stock shares to the public for the first time and at least some of the shares of stock in their company are publicly traded on the public stock markets. At BPIQ.com, our focus is on companies that are publicly traded on the U.S. stock markets. There are many U.S. government rules and regulations that apply to a company that is publicly traded on a U.S. stock market. BPIQ.com provides data on biopharma companies with market caps below $5 billion that are already publicly traded on the U.S. stock markets. To keep this as updated as possible, we continually add companies that recently became public, usually through an IPO, to our database of over 500 companies and their clinical stage or approved assets. While our database is mostly composed of companies with a market cap of at least $100M, some of these recently added companies have a lower market cap; however, we add some companies with market caps under $100M that have recently gone public if they have ongoing Phase 1, 2, or 3 clinical trials.
The last few years have been active years for biotech IPOs. 2020 was very active for biotech IPOs, likely because the public biotech market was red hot as the pandemic drove investors into biotech stocks. 2018 produced 38 offerings of at least $50M, 2019 produced 44, and 2020 produced 71. In the first half of 2021, there were 49 biotech companies that went public. (https://www.biopharmadive.com/news/biotech-ipo-performance-q1-q2-2021/602628/). The pandemic has also drastically changed the focus of biotech companies (41% in diagnostics, 32% in COVID vaccines, and 32% in COVID therapeutics), which is seen as well in the indications of focus in these newly traded companies. (https://www.bdo.com/insights/industries/life-sciences/the-biotech-ipo-boom).
At BPIQ.com, we plan to continually monitor IPOs to identify new public biopharmaceutical companies with assets in clinical trials, and these companies will be added to BPIQ.com throughout the year. Since November two additional biotech cojmpanies have been IPOd, both which are in clinical trials. To learn more about these companies, see upcoming catalysts, and see additional priced companies still in preclinical trials read our forum post HERE after signing up for a BPIQ premium subscription. Learn more here.
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”